, Volume 11, Issue 2, pp 65-69
Date: 24 Feb 2012

What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Therapy with currently available oral nucleos(t)ide analogs (NA) in patients with chronic hepatitis B (CHB, HBeAg-positive or -negative) should ultimately aim at preventing progression to cirrhosis and hepatocellular carcinoma. Since these hard to achieve clinical outcomes evolve over several decades, a number of intermediate therapy end-points i.e. virological, biochemical, serological and histological have been proposed. For HBeAg-positive CHB, durable HBeAg seroconversion remains the gold standard clinical end-point while for HBeAg-negative CHB sustained HBV DNA suppression and HBsAg loss represent the desirable goals to be reached. In this review, the distinguishing features and therapeutic end-points of HBeAg-positive vs—negative CHB are critically presented.